News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2018 IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions L.A. McKeown November 06, 2018
News Conference News VIVA 2016 Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions L.A. McKeown September 22, 2016
News Conference News VIVA 2016 Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent L.A. McKeown September 20, 2016